E-Mail
IMAGE: The collaborative team successfully used their computer-guided design tool IRENE to reconstruct the gene regulatory network controlling the identity of induced pluripotent stem cells (iPSCs). view more
Credit: Wyss Institute at Harvard University
(BOSTON) There is a great need to generate various types of cells for use in new therapies to replace tissues that are lost due to disease or injuries, or for studies outside the human body to improve our understanding of how organs and tissues function in health and disease. Many of these efforts start with human induced pluripotent stem cells (iPSCs) that, in theory, have the capacity to differentiate into virtually any cell type in the right culture conditions. The 2012 Nobel Prize awarded to Shinya Yamanaka recognized his discovery of a strategy that can reprogram adult cells to become iPSCs by providing them with a defined set of gene-regulatory transcription factors (TFs). However, progressing from there
Share this article
Share this article
BOSTON, Feb. 17, 2021 /PRNewswire/ The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard University
E-Mail
IMAGE: The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with the GBS s transistor technology in developing a multiplexed. view more
Credit: Wyss Institute at Harvard University
(BOSTON) The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
Harvard s Wyss Institute collaborates with GBS Inc on the Wyss eRapid-based COVID-19 diagnostic to help curb the pandemic apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Wyss Institute researchers have developed eRapid technology as an affinity-based, low-cost electrochemical diagnostic sensor platform for the multiplexed detection of clinically relevant sepsis biomarkers in whole blood. view more
Credit: Wyss Institute at Harvard University
(BOSTON) Many life-threatening medical conditions, such as sepsis, which is triggered by blood-borne pathogens, cannot be detected accurately and quickly enough to initiate the right course of treatment. In patients that have been infected by an unknown pathogen and progress to overt sepsis, every additional hour that an effective antibiotic cannot be administered significantly increases the mortality rate, so time is of utmost essence.